Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 2/20 | 0.45 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669412 | 0.88 | DHODH (0.51) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL4666988 | 0.85 | SMN1; SMN2 (0.51) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL27704348 | 0.82 | LMNA (0.52) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL8267472 | 0.81 | LMNA (0.82) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL14492079 | 0.81 | PDE10A (0.68) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL6957665 | 0.81 | DHODH (0.65) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL4245187 | 0.81 | DHODH (0.65) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL1581252 | 0.81 | DHODH (0.65) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL4668167 | 0.81 | LMNA (0.74) | LMNATACR3TACR2 | |
| SCHEMBL4990828 | 0.80 | TACR3 (0.60) | CYP2D6CYP2C19TACR3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| CN-101189211-A | Quinoline derivatives as NK3 anatgonists | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | CN | disclosed |
| EP-1891012-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130080-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | KCNQ3, KCNA3, KCNK3 | DHODH 2651/4885PDE10A 1093/4885LMNA 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.